Literature DB >> 11377677

Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis.

W R Sperr1, L Escribano, J H Jordan, G H Schernthaner, M Kundi, H P Horny, P Valent.   

Abstract

In the present study, cytological properties of bone marrow mast cells (MC) were analyzed and correlated with clinical parameters in 69 patients with systemic mastocytosis (SM). Based on cytomorphological features, four distinct cell types were recorded: (i) typical tissue MC (round cells, well granulated, round central nuclei); (ii) atypical MC exhibiting elongated cytoplasmic extensions, oval nuclei with excentric position, and a hypogranulated cytoplasm with focal granule accumulation ('atypical MC type I'); (iii) atypical MC with bi- or multilobed nuclei ('atypical MC type II'); and (iv) metachromatically granulated blast-like cells. In the majority of cases with SM, the percentage of MC in bone marrow (bm) smears was less than 5% (of all nucleated bm cells), and the predominant types were typical MC or atypical MC type I. In a smaller group of patients, the percentage of MC was greater than 5% and a significant subset of MC (>or=10%) were classified as 'metachromatic blasts' and/or atypical MC type II. These patients had a significantly shorter survival (P<0.05) and most of them were found to lack UP-like skin lesions. A percentage of MC>or=20% was invariably associated with the diagnosis 'mast cell leukemia'. Multivariate analysis confirmed the prognostic value of the cytology in SM and identified the percentage of MC (of all nucleated bm cells) as an independent prognostic variable. These data suggest that cytomorphological assessment of bm MC in SM is an important diagnostic approach that may help to delineate between variants of the disease.

Entities:  

Mesh:

Year:  2001        PMID: 11377677     DOI: 10.1016/s0145-2126(01)00041-8

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  42 in total

1.  Systemic mastocytosis: progressive evolution of an occult disease into fatal mast cell leukemia: unique findings on an unusual hematological neoplasm.

Authors:  T Gülen; B Sander; G Nilsson; J Palmblad; K Sotlar; H-P Horny; H Hägglund
Journal:  Med Oncol       Date:  2012-06-03       Impact factor: 3.064

Review 2.  Urticaria pigmentosa and mastocytosis: the role of immunophenotyping in diagnosis and determining response to treatment.

Authors:  Cem Akin; Peter Valent; Luis Escribano
Journal:  Curr Allergy Asthma Rep       Date:  2006-07       Impact factor: 4.806

3.  High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V.

Authors:  Robert Fritsche-Polanz; Marika Fritz; Andrea Huber; Karl Sotlar; Wolfgang R Sperr; Christine Mannhalter; Manuela Födinger; Peter Valent
Journal:  Mol Oncol       Date:  2010-04-24       Impact factor: 6.603

Review 4.  Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.

Authors:  Cem Akin
Journal:  J Mol Diagn       Date:  2006-09       Impact factor: 5.568

5.  Detection of circulating mast cells in advanced systemic mastocytosis.

Authors:  J S Dahlin; J S Ungerstedt; J Grootens; B Sander; T Gülen; H Hägglund; G Nilsson
Journal:  Leukemia       Date:  2016-04-27       Impact factor: 11.528

Review 6.  Proposed diagnostic criteria and classification of basophilic leukemias and related disorders.

Authors:  P Valent; K Sotlar; K Blatt; K Hartmann; A Reiter; I Sadovnik; W R Sperr; P Bettelheim; C Akin; K Bauer; T I George; E Hadzijusufovic; D Wolf; J Gotlib; F-X Mahon; D D Metcalfe; H-P Horny; M Arock
Journal:  Leukemia       Date:  2017-01-16       Impact factor: 11.528

7.  Long-lasting complete response to imatinib in a patient with systemic mastocytosis exhibiting wild type KIT.

Authors:  Peter Valent; Sabine Cerny-Reiterer; Gregor Hoermann; Wolfgang R Sperr; Leonhard Müllauer; Christine Mannhalter; Hubert Pehamberger
Journal:  Am J Blood Res       Date:  2014-12-15

8.  International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis.

Authors:  Jason Gotlib; Animesh Pardanani; Cem Akin; Andreas Reiter; Tracy George; Olivier Hermine; Hanneke Kluin-Nelemans; Karin Hartmann; Wolfgang R Sperr; Knut Brockow; Lawrence B Schwartz; Alberto Orfao; Daniel J Deangelo; Michel Arock; Karl Sotlar; Hans-Peter Horny; Dean D Metcalfe; Luis Escribano; Srdan Verstovsek; Ayalew Tefferi; Peter Valent
Journal:  Blood       Date:  2013-01-16       Impact factor: 22.113

9.  Guidelines and diagnostic algorithm for patients with suspected systemic mastocytosis: a proposal of the Austrian competence network (AUCNM).

Authors:  Peter Valent; Elisabeth Aberer; Christine Beham-Schmid; Christina Fellinger; Wolfgang Fuchs; Karoline V Gleixner; Rosemarie Greul; Emir Hadzijusufovic; Gregor Hoermann; Wolfgang R Sperr; Friedrich Wimazal; Stefan Wöhrl; Brigitte Zahel; Hubert Pehamberger
Journal:  Am J Blood Res       Date:  2013-05-05

10.  Mastocytosis: a paradigmatic example of a rare disease with complex biology and pathology.

Authors:  Peter Valent
Journal:  Am J Cancer Res       Date:  2013-04-03       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.